Recent Updates — NVACW
Profusa entered into Amendment No. 4 to its Note Modification and Conversion Agreement with NorthView Sponsor I LLC on November 5, 2026. The amendment changes the conversion price of the promissory note to the greater of a $0.20 floor price or the closing stock price on the day preceding the conversion notice. This adjustment applies to conversions initiated on or after the effective date. Profusa operates in the biotechnology sector, developing photodynamic therapies for cancer treatment.
On October 15, 2026, Profusa issued a Senior Secured Convertible Promissory Note with a principal amount of $769,230.77 for a purchase price of $700,000 to Ascent Partners Fund LLC under an existing Securities Purchase Agreement. The note bears interest at 7% per annum and matures on October 15, 2027 or upon the closing of a previously announced option exercise. It is convertible into common stock at $4.28 per share, subject to a floor price of $1.07. Monthly amortization payments begin January 1, 2027, and the note is secured by intellectual property assets. Profusa develops photobiomodulation technologies for medical devices.
On October 5, 2026, Profusa dismissed CBIZ CPAs P.C. as its independent registered public accounting firm, effective for the fiscal year ending December 31, 2026. The Audit Committee approved the change due to material weaknesses in internal control over financial reporting related to segregation of duties and valuation controls that remained unremediated as of June 30, 2026. On October 6, 2026, Profusa engaged WithumSmith+Brown, PC as its new auditor. There were no disagreements with CBIZ on accounting principles or auditing scope. Profusa develops photobiomodulation devices for medical and wellness applications.
On October 4, 2026, Profusa entered into amendments with Ascent Partners Fund LLC regarding Senior Secured Convertible Promissory Notes issued in April 2026. The amendments revise the conversion price mechanism to the greater of $1.20 or 95% of the five-day VWAP, establishing a fixed floor price of $0.338 per share. Ascent also waived anti-dilution provisions for three additional notes issued in August and September 2026. Profusa operates in the biotechnology sector, developing photobiomodulation therapies.
On September 18, 2026, Profusa, Inc. held a Special Meeting of Stockholders where shareholders approved an amendment to the Certificate of Incorporation granting the Board discretion to effect one or more reverse stock splits within the next two years. The authorized range is 1-for-2 to 1-for-12, with the aggregate split not exceeding 1-for-12; specific ratios and timing remain at the Board's discretion without further shareholder approval. The proposal passed with 262,920 votes in favor against 17,360 opposed. Profusa, Inc. operates in the biotechnology industry, developing photobiomodulation therapies.
On September 16, 2026, Profusa, Inc. completed an additional closing under its Securities Purchase Agreement with Ascent Partners Fund LLC by issuing a Senior Secured Convertible Promissory Note with a principal amount of $384,615.38 for a purchase price of $350,000. The note bears 7% annual interest payable monthly and matures on September 16, 2027, or upon an Option Closing Date. It is convertible into common stock at $4.28 per share, subject to a floor price of $1.07, and includes mandatory prepayment obligations tied to future offerings. Profusa operates in the biotechnology sector, developing photobiomodulation therapies.